<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141011019489N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-20</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of a natural cream on hemorrhoids in comparison with the conventional ointment</public_title>
      <acronym></acronym>
      <scientific_title>Effect of a natural cream on hemorrhoids in comparison with conventional anti-hemorrhoid ointment: A double-blind controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45941</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We use two variables to remove the effect of confounding factors: age and weight. In this method, the effect of the abovementioned two variables is controlled via analysis of variance. So, the effect of the independent variable (drug) on the dependent variable will be determined. 
To control age and weight we use randomized block design, i.e. quadratic blocks for weight and binary blocks for age. According to that, the samples will be allocated into A and B groups, Blinding description: The main researcher does not have any contact with the participants. 
The gastroenterologist only visits the participants and fills out the checklists. So, he will be kept unaware of the allocation into A or B groups. 
Moreover, the participants and the pharmacy technician who renders the ointments do not recognize the tubes (A or B) belonging to which group (drug or control). All tubes are the same form.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Hemorrhoid. Condition 2: Hemorrhoid.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Herbal cream containing the extract of oleaster, wild leek and camomile, and the essence of common myrtle. Route of administration and dose: Locally one gram on the anal region by a special applicator twice daily for 14 days. Manufacturer: Barij Essence Pharmaceutical Company. Intervention 2: Control group: Anti-hemorrhoid ointment (containing lidocaine 5 grams+Hydrocortisone Acetate 0.275 grams+ Aluminium sub-acetate 3.5 grams+ Zinc oxide 18 grams%). Route of administration: Locally on the anal region by a special applicator twice daily for 14 days. Manufacturer:  Aburaihan Pharmaceutical Company/Barij Essence Pharmaceutical Company. An edible green color is used for the placebo to change the color similar to the drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The publication of data is restricted on demographic information and values obtained from the diagnostic checklist for hemorrhoids. This data will be published unrecognizably in the form of scientific articles in authentic journals.

When:
From March 2021 to March 2022

To whom:
All audiences

Conditions:
The data can be used for similar researches under the prohibition of plagiarism

Where to obtain:
The data is available online for all audiences

How to obtain:
There is no process for obtaining information

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Ebrahim Zohalinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3208 4241</telephone>
        <email>zohalinm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Meysam Shirzad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 25 Sarparast Ave., Taleqani St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416663361</zip>
        <telephone>+98 21 8899 3656</telephone>
        <email>shirzad@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age: 18 and more
Hemorrhoid Grade 1,2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any types of malignancy
Hypertension
Hepatic or renal failure
Diabetes mellitus</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64.0</hc_code>
      <hc_code>K64.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>First degree hemorrhoids</hc_keyword>
      <hc_keyword>Second degree hemorrhoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Herbal cream containing the extract of oleaster, wild leek and camomile, and the essence of common myrtle. Route of administration and dose: Locally one gram on the anal region by a special applicator twice daily for 14 days. Manufacturer: Barij Essence Pharmaceutical Company</i_keyword>
      <i_keyword>Control group: Anti-hemorrhoid ointment (containing lidocaine 5 grams+Hydrocortisone Acetate 0.275 grams+ Aluminium sub-acetate 3.5 grams+ Zinc oxide 18 grams%). Route of administration: Locally on the anal region by a special applicator twice daily for 14 days. Manufacturer:  Aburaihan Pharmaceutical Company/Barij Essence Pharmaceutical Company. An edible green color is used for the placebo to change the color similar to the drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Manifestations of hemorrhoid. Timepoint: The onset of the intervention, 2 weeks later, 6 weeks later. Method of measurement: A checklist for hemorrhoid manifestations including 1- Anal pain (VAS zero to 10) 2- Difficulty in defecation (VAS zero to 10) 3- Bleeding severity (4-point Likert) 4- Anal pruritus (4-point Likert) 5- Anal burning (4-point Likert) 6- Subjective general improvement (percent).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Barij essence pharmaceutical company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-09</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>6th Floor,  Central building of Shiraz University of Medical Sciences  Zand St., Shiraz, Iran Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
